An essential function of the extreme C-terminus of MDM2 can be provided by MDMX

EMBO Journal

Volumn 26, Issue 1, 2007, Pages 102-112

  Uldrijan, Stjepan ^a   Pannekoek, Willem Jan ^a,b   Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

E3; MDM2; MDMX; p53; Ubiquitin

Indexed keywords

MUTANT PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBRYO; ENZYME ACTIVITY; GENE DELETION; HUMAN; HUMAN CELL; OLIGOMERIZATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTATION; NUCLEAR PROTEINS; POINT MUTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 33846193699     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7601469     Document Type: Article

References (49)

1. Argentini M, Barboule N, Wasylyk B (2001) The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20: 1267-1275
2. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164-171
3. Brooks CL, Gu W (2006) p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315
4. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M (2005) Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets 5: 57-68
5. Chen J, Lin J, Levine AJ (1995) Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1: 142-152
6. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J (2005) ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 24: 3411-3422
7. Dang J, Kuo ML, Eischen CM, Stepanova L, Sherr CJ, Roussel MF (2002) The RING domain of Mdm2 can inhibit proliferation. Cancer Res 62: 1222-1230
8. de Graaf P, Little NA, Ramos YF, Meulmeester E, Letteboer SJ, Jochemsen AG (2003) HdmX protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 278: 38315-38324
9. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951
10. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC (2006) Mdm2 and MdmX cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 103: 3232-3237
11. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G (2006) Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26: 92-198
12. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM (2002) Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 277: 19251-19254
13. Jackson MW, Berberich SJ (2000) MdmX protects p53 from Mdm2-mediated degradation. Mol Cell Biol 20: 1001-1007
14. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embyonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208
15. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM (2003a) DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 278: 45946-45953
16. Kawai H, Wiederschain D, Yuan ZM (2003b) Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23: 4939-4947
17. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE (2006) Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol 363: 433-450
18. Lai Z, Freedman DA, Levine AJ, McLendon GL (1998) Metal and RNA binding properties of the hdm2 RING finger domain. Biochemistry 37: 7005-7015
19. Lebron C, Chen L, Gilkes DM, Chen J (2006) Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J 25: 1196-1206
20. Li C, Chen L, Chen J (2002) DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms. Mol Cell Biol 22: 7562-7571
21. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M (2003) HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 100: 12009-12014
22. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G (2006) Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927-934
23. Meek DW, Knippschild U (2003) Posttranslational modifications of MDM2. Mol Cancer Res 1: 1017-1026
24. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME (2003) mdm2 is critical for inhibition of p53 during lympopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462-472
25. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH, Jochemsen AG (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Biol Cell 23: 4929-4938
26. Meulmeester E, Maurice MM, Boutell C, Teunisse AFAS, Ovaa H, Abraham TE, Dirks RW, Jochemsen AG (2005) Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of HdmX and Hdm2. Mol Cell 18: 565-576
27. Migliorini D, Danovi D, Colombo E, Carbone R, Pelicci PG, Marine JC (2002a) HdmX recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J Biol Chem 277: 7318-7323
28. Migliorini D, Lazzerini-Denchi E, Danovi D, Jochemsen AG, Capillo M, Gobbi A, Helin K, Pelicci PG, Marine JC (2002b) Mdm4 (MdmX) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22: 5527-5538
29. Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459
30. Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine JC, Prives C, Shiloh Y, Jochemsen AG, Taya Y (2005) DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol 25: 9608-9620
31. Pan Y, Chen J (2003) MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 23: 5113-5121
32. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92-95
33. Poyurovsky MV, Priest C, Kentsis A, Borden KLB, Pan Z-Q, Pavletich N, Prives C. The MDM2 ring domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. (Submitted)
34. Ryan KM, Phillips AC, Vousden KH (2001) Regulation and function of the p53 tumor suppressor protein. Curr Biol 13: 332-337
35. Sharp DA, Kratowicz SA, Sank MJ, George DL (1999) Stabilization of the MDM2 oncogene by interaction with the structurally related MDMX protein. J Biol Chem 274: 38189-38196
36. Sharpless NE (2005) INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576: 22-38
37. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RCA, van der Houven van Oordt W, Hateboer G, van der Ed AJ, Jochemsen AG (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 15: 5349-5357
38. Silke J, Kratina T, Chu D, Ekert PG, Day CL, Pakusch M, Huang DC, Vaux DL (2005) Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci USA 102: 16182-16187
39. Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK, Jochemsen AG (2001) MdmX stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep 2: 1029-1034
40. Stad R, Ramos YF, Little N, Grivell S, Attema J, van der Eb AJ, Jochemsen AG (2000) HdmX stabilizes Mdm2 and p53. J Biol Chem 275: 28039-28044
41. Stommel JM, Wahl GM (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 23: 1547-1556
42. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M (1999) MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 447: 5-9
43. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, King N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecular antagonists of MDM2. Science 303: 844-848
44. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
45. Vousden KH (2002) Activation of the p53 tumor suppressor gene. Biochem Biophys Acta 1602: 47-59
46. Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH (2005) HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 24: 1965-1972
47. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G (2006) Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci USA 103: 3226-3231
48. Yang Y, Ludwig RL, Jensens JP, Pierre S, Medaglia MV, Davydov I, Safiran YJ, Oberoi P, Kenten J, Phillips AC, Weissman AM, Vousden KH (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7: 547-559
49. Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, Fersht AR (2006) The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci USA 103: 1227-1232